Verastem, Inc.

VSTM ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Operating Activities
Net Income $-67.8M $-36.4M $-57.9M $-53.4M $-41.2M $-32.0M $-13.7M
Depreciation & Amortization $670.0K $754.0K $427.0K $236.0K $207.0K $83.0K
Depreciation $556.0K $670.0K $754.0K $427.0K $236.0K $207.0K $83.0K
Amortization
Stock-Based Compensation $5.0M $6.3M $10.1M $12.4M $9.7M $7.4M $1.6M
Net Cash from Operating Activities $-57.3M $-29.5M $-45.6M $-36.9M $-26.3M $-22.6M $-9.4M
Investing Activities
Capital Expenditures $39.0K $211.0K $2.4M $56.0K $310.0K $785.0K
Business Acquisitions
Net Cash from Investing Activities $44.0M $36.9M $-27.1M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $63.2M $-5.0K $63.6M
Net Change in Cash $49.8M $7.5M $-9.0M
Free Cash Flow $-29.5M $-45.8M $-39.3M $-26.4M $-22.9M $-10.2M
← Newer Page 2 of 2 Older →